CDH1 and breast carcinoma: Our results show that atropine may bind to E-cad and ZEB-2, thus helping to reduce the breast cancer metastatic development and resistance to chemotherapy in two cell lines from different origins, the aggressive claudin-low mesenchymal-like cells, and the T47D cells, which is a luminal A epithelial-like cell line.